Latest Industry Insights

Scientists around the world are increasingly aware of the environmental footprint of their laboratories, and many are adjusting the way they work day-to-day to offset this impact. In this Industry Insights interview, Agilent's Dr. Michael Frank discusses the safety and efficiency considerations that are fundamentally linked to sustainability and considers why more labs aren’t utilizing consulting services to help them achieve their sustainability goals.

How can the industry as a whole address sustainability issues? What are the key needs and goals of pharma and biopharma laboratories when it comes to sustainability?

BetterLife Pharma’s lead candidate is a non-hallucinogenic derivative of LSD that mimics the projected therapeutic properties of LSD. To learn more, we spoke with BetterLife Pharma’s chief operating officer, Dr. Hooshmand Sheshbaradaran, and head of preclinical research, Dr. Abdi Ghaffari.

HPLC system manufacturers have been striving to improve usability, accessibility and help users improve their experimental outcomes. And what better way to do that than to involve the users themselves in that development process.

To learn more about the progress and development of non-hallucinogenic psychedelic therapies for conditions such as depression, Technology Networks spoke with the head of research and development at Delix Therapeutics, Dr. Eliseo Salinas.

Explore the importance of location-specific expertise in global research collaborations and how to overcome challenges faced by in-house R&D teams when engaging with global partners.

We spoke to Prof. Oscar Ces, head of the Department of Chemistry at Imperial College London (ICL), to find out about the evolution of ICL’s White City Campus, the Agilent Measurement Suite and what it means for scientists across the board.

Hear how the capabilities of mass spectrometry (MS)-based proteomics are proving themselves in drug development and discovery and what this means for those working in oncology.

Revvity announced its newly established Scientific Centre of Excellence in Cambridge, where scientists can outsource their research needs to Revvity experts. Technology Networks visited the site to learn more about how Revvity is supporting its customers in their drug discovery efforts.

Trial sponsors are faced with vast amounts of diverse data and corresponding endpoints spanning all trial sites linked to their study design. This article explores how interactive response technology can help sponsors overcome these challenges.